The University of Memphis unveiled a new initiative and degree program "aligned with [regional] workforce needs." ...

Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS ...

Optum, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in an ...

ITM Isotope Technologies Munich SE is gearing up to enter the US market with its radiopharmaceutical therapy, ITM-11 ...

Discover how FTRE's $7.7B backlog, CRO market growth, and focus on high-margin areas ensure long-term growth, efficiency, and ...

Pharmaceuticals (SCPH) announced that the FDA has approved the supplemental new drug application for Furoscix to expand the indication to ...

The federal government has spent $6.2 billion on research and development for weight-loss drugs. Now, thanks to Big Pharma ...

After the contentious Senate confirmation of Robert F. Kennedy Jr., another crucial governmental health leadership ...

The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...

Tris Pharma previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.